Ghana could be paying up to 30 times more than the recommended price for medicines, a new report says.
According to the report by the Center for Global Development (CEG), lower to middle-income countries such as Ghana, Ethiopia, Kenya and Nigeria, are losing out when purchasing what it calls branded generic drugs.
It said the kinds of medicines affected range from basic pain killers, to statins to treat blood pressure and herceptin for breast cancer treatment.
“Purchasers in low- and middle-income countries pay as much as 20 to 30 times a minimum international reference price for basic generic medicines like omeprazole, used to treat heartburn, or paracetamol, a common pain reliever,” the report said.
Author of the report, Amanda Glassman told the BBC that one of the problems is that many countries are buying these branded drugs when it would be cheaper to acquire what she described as “unbranded quality-assured drugs” – guaranteed medicines which do not have an internationally recognised drug company name associated with them.
“In the poorest countries, branded generics—which command a price premium—make up about two-thirds of the market by volume and value. Unbranded generics, usually the least expensive option, are a tiny sliver, only 5 percent of the market by volume and 3 percent by value. In contrast, in the United States and the United Kingdom, unbranded quality-assured generics account for 85 percent of the pharmaceutical market by volume, but only about a third by cost,” the report said.
The report added that many countries do not have a coordinated drug purchasing policy meaning that they are unable to negotiate a lower price.
“…in lower-middle-income countries, 80 percent of health products are procured through the private sector, where individuals pay directly for medicines out-of-pocket. Lower-middle-income country governments do not yet account for a large share of total purchasing in their countries for medicines and other health products,” it added.
The CDG says affordable drugs are necessary and in their absence, “lasting health gains will remain elusive”.